Adipotide
Evidence: CMetabolic / Weight Management
Evidence Snapshot
What this grade covers
A for molecular identity; B for selected rodent and nonhuman-primate findings; C/D for registered first-in-human development context; E for established human weight loss, approval, safety, or dosing.
Regulatory Context
Investigational prohibitin-targeting peptidomimetic; not FDA-approved. A first-in-human phase 1 study was terminated and verified published results were not located.
Research Takeaway
Adipotide is a prohibitin-targeted proapoptotic peptidomimetic designed to direct a mitochondria-disrupting D(KLAKLAK)2 payload toward the vasculature of white adipose tissue; evidence from unconjugated KLAK peptides, generic prohibitin inhibitors, or other vascular-targeting constructs must not be treated as adipotide evidence.
Evidence boundary: Exact construct identity matters because both the targeting ligand and the proapoptotic payload determine the reported biological effect.
See all 6 evidence claims →Quick Summary
Adipotide is a vascular-targeting proapoptotic peptidomimetic designed to bind prohibitin on white-adipose-tissue vasculature and deliver a mitochondria-disrupting sequence. Weight-loss findings come mainly from mouse and nonhuman-primate studies; a first-in-human trial was registered but terminated without verified published outcome results.
Mechanism & Research Overview
Adipotide combines the adipose-vasculature-homing motif CKGGRAKDC with a proapoptotic D(KLAKLAK)2 sequence. The targeting portion binds prohibitin associated with white-adipose vasculature, while the proapoptotic component disrupts mitochondrial membranes in targeted vascular cells, leading to loss of adipose blood supply in preclinical models.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Adipotide is a prohibitin-targeted proapoptotic peptidomimetic designed to direct a mitochondria-disrupting D(KLAKLAK)2 payload toward the vasculature of white adipose tissue; evidence from unconjugated KLAK peptides, generic prohibitin inhibitors, or other vascular-targeting constructs must not be treated as adipotide evidence.
Does not establish
Evidence boundary: Exact construct identity matters because both the targeting ligand and the proapoptotic payload determine the reported biological effect.
Supported
In preclinical models, adipotide targets prohibitin-associated white-adipose vasculature and promotes vascular-cell injury/apoptosis, followed by loss of established white adipose tissue.
Does not establish
Evidence boundary: This is a preclinical mechanism and does not establish a safe or effective human fat-loss treatment.
Supported
In obese rhesus macaques, adipotide produced substantial reductions in body weight, BMI, abdominal circumference, and measured fat volume, with improvement in indices of insulin resistance during treatment.
Does not establish
Evidence boundary: These were nonhuman-primate studies; the magnitude of weight loss cannot be presented as expected human efficacy.
Supported
Nonhuman-primate studies identified dose-related renal tubular toxicity and changes including creatinine elevation, glucosuria, and proteinuria; many abnormalities improved after treatment stopped, but renal injury is a material safety signal.
Does not establish
Evidence boundary: Reversibility in experimental animals does not establish renal safety in humans.
Supported
A registered first-in-human Phase I study of Prohibitin-TP01 exists, but a trial registry entry is not evidence that adipotide has established human obesity efficacy.
Does not establish
Evidence boundary: Human-development status must be separated from completed, peer-reviewed clinical efficacy.
Supported
Adipotide should be described as an experimental compound without an established approved human obesity indication in this evidence package.
Does not establish
Evidence boundary: This claim does not attempt to characterize every jurisdiction; it defines the evidence boundary relevant to the MitoCore page.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Renal proximal-tubule changes were reported in obese-monkey research.Safety Consideration
The mechanism intentionally injures targeted vasculature, creating substantial theoretical and observed safety concerns.Safety Consideration
No verified published human efficacy or safety results were located from the terminated phase 1 registry.Safety Consideration
Reduced food intake may have contributed to some primate weight-loss findings, according to published commentary.Safety Consideration
The catalog acronym FTTP should be retained only as a catalog spelling; FTPP is the literature acronym for fat-targeted proapoptotic peptide.Safety Consideration
Polyuria and dehydration accompany the reported renal proximal-tubule changes. Off-target vascular injury, apoptosis outside the intended adipose endothelium, and altered prohibitin/annexin-A2 biology are mechanism-level concerns. Hepatic, cardiac, neurologic, reproductive, developmental, immune, and oncologic effects are uncharacterized in humans. Immunogenicity, D-amino-acid impurity, aggregation, sterility, endotoxin risk, and repeated-course/long-term safety are unknown.
Research Areas Being Studied
Research areas discussed on this page reflect the Metabolic / Weight Management category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| NCI Drug Dictionary: Prohibitin-Targeting Peptide 1 | NCI's Drug Dictionary describes prohibitin-targeting peptide 1 (Adipotide/Prohibitin-TP01) as an investigational chimeric peptidomimetic that combines a prohibitin-targeting domain with a proapoptotic sequence and notes potential antineoplastic activity. NCI does not describe an FDA-approved product or an established human obesity indication. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| First Patient Dosed in Adipotide Phase I Study | Sponsor newsroom announcement describing dosing of the first patient in the Phase I Prohibitin-TP01/Adipotide study. Development-context material only -- not a peer-reviewed report of human weight-loss efficacy or outcome data, and registry status plus a company announcement do not by themselves establish published human efficacy. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-30.
Follow research updates for Adipotide
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.